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Abstract
Thromboembolic manifestations like pulmonary embolism and deep venous thrombosis are often reported and
contribute to a signiﬁcant mortality from acute and chronic COVID-19 infections. These phenomena are a result of the
activation of the coagulation cascade by the COVID-19 induced inﬂammatory state.
Majority of the thrombotic incidences are reported as a venous thrombosis but extremely rarely, arterial thrombi can
be a manifestation of acute COVID-19 infection.
The patient in our case report was an unvaccinated 47-year-old female who presented with fever, nausea, abdominal
pain and vomiting. The imaging conﬁrmed the presence of a non-occlusive thrombus in the descending aorta, multiple
splenic infarctions and paralytic ileus. She was treated with systemic anti-coagulation. A hyper-coagulable workup was
performed on the patient and no other risk factors that could contribute to a thrombus was identiﬁed.
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1. Introduction

A

mong the many other typical and atypical
presentations of the novel SARS-CoV-2
(COVID-19) infection, it frequently results in
markedly dysregulated coagulation cascade, leading
to heightened risk of thrombotic events and significant morbidity and mortality.1e6 These thrombotic
complications range from myocardial infarction,
venous thromboembolic diseases to acute cerebrovascular attacks.7 Although its prothrombotic pathophysiology is still not completely understood, the
COVID-19 associated coagulopathy is thought to be
a consequence of up-regulation of several inﬂammatory and immune-mediated pathways that are
inter-connected and auto-amplifying.7 The microvascular and macro-vascular thrombosis can effect
the vasculature of many organs including lungs,
heart, brain and spleen.3 While pulmonary embolism and deep venous thrombosis account for a
majority of thromboembolic manifestations of

COVID-19, there have been reported cases of
thrombosis in the aorta as well as other major
vessels.4
This case report illustrates a case of a large acute
thrombus in the descending aorta as a complication
of COVID-19. The presentation was further
complicated by formation of splenic infarctions,
paralytic ileus and resultant bacteremia. The case
report illustrates the challenges in it's diagnoses as a
result of non-speciﬁc features, and provides a literature review of the thrombotic complications associated with COVID-19.

2. Case presentation
The patient was a 47-year-old obese caucasian
female with an underlying history of untreated
obstructive sleep apnea. She was a non-smoker and
had no personal history of asthma, COPD, diabetes,
hypertension, or cardiac disease.
She tested positive for Covid-19 in September,
2021. She was unvaccinated at that time. Her sick
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contact was her husband who also was positive for
COVID-19 during that period. She described loss of
sense of taste and smell, periodic nausea with episodes of vomiting, diarrhea, fatigue, fevers and
chills. Later she developed a cough, associated with
shortness of breath with minimal exertion. With the
worsening of shortness of breath, she presented to
the emergency room ten days after being positive
for COVID-19.
She was febrile in the emergency room with a
temperature of 101.1 F. Chest x-ray showed minor
bi-basilar inﬁltrates [Fig. 1]. She was hypoxic with
an oxygen saturation of 88% on room air. Rest of the
blood work was unremarkable except for an elevation in the inﬂammatory markers. At the time of
admission, her white cell count was 10,900/uL
(reference range 4500 to 11,000/uL), CRP level was
76.1 mg/L (reference range 0e8 mg/L), interleukin-6
level 13.9 pg/ml (reference rage 0e7 pg/ml), Ddimer level 193 ng/ml (normal high <244 ng/ml),
LDH level was normal at 187 units/L (reference
range 140e280 units/L).
She was started on supplemental oxygen through
nasal cannula and high-dose intravenous steroids.
Intravenous remdesivir was not considered since it
had already been ten days since she tested positive.
After a 3-day uncomplicated stay in the hospital, the
patient was weaned off of oxygen and was discharged home on a steroid taper. During the hospital course, she also endorsed some right-sided leg
cramping which resolved spontaneously with as
needed doses of acetaminophen. She received

Fig. 1. Bibasilar inﬁltrates from COVID-19 infection.
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standard subcutaneous anticoagulation DVT prophylaxis with subcutaneous heparin.
Three days later, the patient presented again to
the emergency department with intractable epigastric pain of one day duration. She stated that the
pain was constant but got worse with any attempt to
eat. She had severe nausea with the pain and few
episodes of emesis that were non-bloody and nonbilious. She denied any diarrhea, sick contacts or
food exposure that might have led to gastroenteritis.
She denied any recurrence of her fevers, chills,
cough, chest pain or shortness of breath.
She received a contrast enhanced CT scan of the
abdomen and pelvis that showed [Fig. 2] nonocclusive ﬁlling defect in the descending thoracic
aorta measuring 28  11  11 mm, likely representing a thrombus and mild fat stranding along the
common origin of celiac trunk and SMA which is
nonspeciﬁc, however may be seen with vasculitis.
No other abnormality in the arterial and venous
vasculature, or acute process in the abdomen and
pelvis.
The CRP level was 16.4 mg/L (reference range
0e8 mg/L). The renal function panel, electrolyte
panel and hepatic panel were completely within
normal limits. She had a leukocytosis of 15,300 cells/
mm3 which was predominantly neutrophilic, this
was considered secondary to the use of systemic
steroids that she was discharged with in the previous admission.
She was admitted, started on anticoagulation with
low molecular weight heparin, 1 mg/kg body weight
twice a day with an intention to transition to direct
oral anticoagulation, once she was able to tolerate
oral diet and medications. The etiology of the

Fig. 2. Non-occlusive thrombus in the descending thoracic aorta
(28  11  11 mm).
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abdominal pain was quite unclear at the time of
admission and multiple differential diagnosis were
considered. COVID-19 induced abdominal pain and
gastroenteritis was a potential diagnosis and the
systemic steroids were continued. Symptomatic
management was offered with pantoprazole and
ondansetron intravenously. The other differential
was occlusion of the superior mesenteric or celiac
arteries by the thrombus, thus leading to postprandial abdominal pain. A Doppler study of the
mesenteric arteries was requested but the study was
inconclusive because of the patient's obese body
habitus. A bilateral venous Doppler excluded deep
venous thrombosis in the lower extremities.
On day 2 of the hospitalization, the patient's
abdominal pain worsened and she had multiple
bouts of emesis. The emesis was bilious and nonbloody. She also developed a low-grade fever. Lactic
acid level was elevated at 3.4 mmol/L. She had a
repeat CT angiogram of the abdomen and the celiac
artery, superior mesenteric artery and rest of the
vasculature were unremarkable. However, there
were several small to moderate sized splenic infarctions. The largest infarction was 2.4 cm [Fig. 3].
On day 3 and day 4 of the hospitalization, the
lactic acid level normalized with intravenous hydration but there was no improvement in her
nausea and vomiting. An obstruction series was
done that showed gaseous distention of the small
bowel loops, up to 4.6 cm in the mid abdomen. The
ﬁndings were concerning for small bowel obstruction and were new compared to the CT scan from 2
days prior [Fig. 4]. A nasogastric tube was inserted
to relieve the obstruction and was managed with
complete bowel rest and intermittent suction. Patient was also noted to be febrile with a temperature

Fig. 4. Distal aortic thrombus leading to small bowel ileus (4.6 cm
gaseous distention of the small bowels).

of 101.2 F. The leukocytosis also worsened to
20,600 cells/mm3. Blood cultures were obtained and
she was empirically started on intravenous Piperacillin/Tazobactam.
The nausea, vomiting and abdominal pain gradually improved. A small bowel follow through
obstruction series performed two days later ruled
out a complete small bowel obstruction. Blood cultures from admission grew pan-sensitive Klebsiella
pneumoniae which likely originated from the bowel.
Antibiotic coverage was downgraded to intravenous
Cefazolin while inpatient and discharged on a 2week course of oral cefuroxime. She was also transitioned to Apixaban on discharge. A complete
hyper-coagulable work up could not be attempted
because of the active thrombus but genetic mutations like prothrombin gene mutation, factor 5 Leiden mutation, anti-cardiolipin antibodies and lupus
anti-coagulant were negative. Follow up CT scan of
chest, abdomen and pelvis two weeks after
discharge revealed decreased size of the thrombus
in the descending aorta [Fig. 5].

3. Discussion

Fig. 3. 2.4 cm splenic infarction noted on day 2 hospitalization from the
aortic thrombus.

Isolated descending thoracic aortic thrombus, to
our knowledge, is an uncommon ﬁnding associated
with COVID-19 infection. Although its exact mechanism is unclear, the SARS-CoV-2 infection creates
pro-thrombotic environment by altering vessel
barrier integrity, promoting pro-coagulative state,

Fig. 5. Resolution of the descending aortic thrombus after 2 weeks of
anticoagulation.

inducing vascular inﬂammation (endotheliitis) and
mediating inﬂammatory cell inﬁltration.8
SARS-Cov-2 infection can directly infect endothelial cells, leading to inﬂammation, apoptosis and
dysfunction.9 The endothelial cell invasion instigates the recruitment of granulocytes and macrophages, synthesizing pro-inﬂammatory cytokines.
As the inﬂammatory process progresses, like in
seriously ill patients, the end result is COVID-19
associated coagulopathy that manifests as arterial
and venous thrombosis. This is a downstream
consequence of the host's inﬂammatory response to
the viral insult and activation of innate immunity.
The thrombus formation is an end-product of a
complex interplay of numerous pathways that
involve cytokine storm, macrophage activation,
complement activation, platelet activation, and
renin-angiotensin system dysregulation.8 The
COVID-19 illness is associated with profound inﬂammatory cytokine response, that is manifested by
an increased expression of IL-1, IL-6, and tumor
necrosis factor (TNF)-a. While IL-1 and TNF-a play
an important part in the suppression of endogenous
anticoagulant pathways, IL-6 triggers the coagulation cascade by inducing tissue factor expression on
endothelial cells.9 This coagulopathy is postulated to
be the primary etiology of acute respiratory distress
syndrome in COVID-19 patients, as it triggers the
formation of ﬁbrin-platelet microthrombi in the
pulmonary microcirculation and parenchyma.10 The
ﬁndings of increased angiogenesis and microangiopathic thrombosis in the pulmonary vasculature of COVID-19 patients who succumbed from
ARDS give more credibility to the hypothesis.11
The presence of signiﬁcant thrombus burden in
the aorta in the absence of vessel wall damage or
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massive atherosclerosis is unexpected in viral infections. However, SARS-CoV-2 infection might be
an exemption. Studies on SARS-CoV-2 have shown
a high speciﬁcity for virus binding to the angiotensin-converting enzyme-2 (ACE-2) receptor as a
mechanism to invade host cells. The ACE-2 receptors are expressed widely in the human body,
including on the vascular endothelium.12 Hence, it
is possible that the aortic thromboembolism in these
patients may be caused by ACE-2 mediated SARSCoV-2 infection of the large vessel wall, resulting in
local injury and intravascular activation of the clotting cascade.
Although the exact incidence of aortic thrombotic
events in COVID-19 infections is unknown, there is
a high likelihood that it would be under-reported
and underestimated given the non-speciﬁc presentation, and their incidental revelation on imaging
studies that are primarily performed for some other
reason. The existence of venous and/or arterial
thromboembolic events, in general, has been underrecognized in patients suffering from a severe
course COVID-19 infection and D-dimer level
measurement at admission can be utilized as an
early tool to facilitate timely recognition.13,14 The
mainstay of therapy is treatment with heparin for
reducing thrombus load in the aorta and for prevention of new thrombi formation. Other treatment
options can include thrombolysis, interventional, or
surgical thrombectomy.14
There have been some reports of thrombotic and
more commonly thrombocytopenic complications
from the different types of COVID-19 vaccinations.15e18 However, there is no evidence to
report that the incidence of thrombotic complications further increases after the vaccination once the
individuals have a thrombotic incident from the
acute COVID-19 infection. The patient in our case
was encouraged to get the vaccine after recovery
from the acute phase.
In light of the increasing incidence of cases, from
the COVID-19 variants, it is even more important to
encourage everyone to take any of the available
vaccines against the virus.19,20

4. Conclusion
In this case report, we report a rare case of
descending aortic thrombus in the setting of
COVID-19 infection. COVID-19 induced arterial or
venous coagulopathy is a consequence of the inﬂammatory pathways amplifying the coagulation
cascade. It is a known fact that pulmonary embolism
and deep venous thrombosis are quite common and
account for a signiﬁcant mortality from COVID-19.
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However, aortic and other major vessel thrombotic
complications have been reported rarely. This lifethreatening complication reinforces the importance
of vaccinations and social distancing in the current
pandemic era.
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